Verrica Pharmaceuticals Inc.(VRCA)Stock Analysis

VRCA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Verrica Pharmaceuticals Inc. (VRCA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VRCA at 26.1/100 on a 32-signal composite quality model, placing it at rank #2,518 of 2,879 stocks — the bottom half of the AI-ranked universe. VRCA scores in the top quartile across revenue growth (95.4). Areas of concern include institutional flow (0.9) and balance sheet strength (4.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Verrica Pharmaceuticals Inc. reports quarterly revenue of $5.0M, net income of $-9.7M, free cash flow of $-9.2M. Top institutional holders of VRCA by reported 13-F value include Caligan Partners, Affinity Asset Advisors,, CANNELL CAPITAL, based on the most recent SEC filings. VRCA trades on the Nasdaq exchange and files with the SEC under CIK 1660334. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VRCA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Verrica Pharmaceuticals Inc. directly from SEC EDGAR. Verrica Pharmaceuticals Inc.'s 13F Pro composite quality score has ranged between 26 and 30 since 2026, currently 26.1 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.